Phospho-WEE1 (S642) Antibody

What is the functional significance of WEE1 phosphorylation at S642?

WEE1 phosphorylation at S642 is a fundamental regulatory event in cell cycle progression. This Akt/PKB-dependent phosphorylation promotes a change in WEE1 localization from nuclear to cytoplasmic compartments and is directly associated with G2/M arrest . This phosphorylation occurs during S and G2 phases and is required for 14-3-3 protein binding . The phosphorylation status at S642 serves as a biomarker of WEE1 kinase activity in cell cycle regulation, with its maximum presence observed during G2 phase and minimum during M phase transition. Functionally, this modification modulates WEE1's ability to phosphorylate and inactivate cyclin B1-complexed CDK1 at Tyr15, thereby preventing premature mitotic entry .

Which techniques are optimal for detecting Phospho-WEE1 (S642) in different sample types?

Multiple techniques can be employed to detect Phospho-WEE1 (S642), each with specific optimization requirements:

For optimal results, researchers should employ phosphatase inhibitors during sample preparation and consider using alkaline phosphatase treatment as a negative control, as demonstrated by the absence of signal following this treatment in multiple validation studies .

How can I confirm the specificity of Phospho-WEE1 (S642) antibody detection in my experimental system?

Confirming antibody specificity requires multiple validation approaches:

• Phosphatase treatment control: Compare untreated membranes with phosphatase-treated membranes. Properly specific phospho-antibodies will show signal reduction or elimination after phosphatase treatment as demonstrated in validation studies .

• Mutant controls: Utilize cells expressing S642A mutant WEE1 (serine-to-alanine mutation at position 642), which prevents phosphorylation at this site. These cells should show minimal or no signal with the phospho-specific antibody .

• Phosphorylation induction: Treat cells with phosphatase inhibitors like Calyculin A (100nM for 30min) to enhance phosphorylation and verify increased signal intensity .

• Downstream marker verification: Confirm functional WEE1 activity by detecting corresponding changes in downstream targets, particularly CDK1 phosphorylation at Y15 .

• Cross-reactivity assessment: Evaluate against proteins with similar phosphorylation motifs to ensure specificity. Most validated antibodies show "no cross-reactivity with other proteins" as stated in their validation documentation .

• Advanced Methodological Considerations

How should experimental design be modified when investigating Phospho-WEE1 (S642) in cancer cell lines versus primary tissue samples?

Research protocols require distinct optimization strategies depending on the experimental material:

For Cancer Cell Lines:

• Baseline phosphorylation of WEE1 S642 varies significantly across neuroblastoma, leukemia, and other cancer lines, requiring appropriate positive controls specific to the cancer type .

• Cell synchronization may be necessary, as WEE1 phosphorylation fluctuates throughout the cell cycle, with peak levels during S and G2 phases .

• The use of therapeutic agents targeting the cell cycle (e.g., AZD1775, HDACIs like Vorinostat) significantly alters S642 phosphorylation patterns, necessitating time-course experiments with sampling points as early as 8 hours post-treatment .

For Primary Tissue Samples:

• Tissue microarray analysis reveals that high-risk neuroblastoma tumors show increased WEE1 phosphorylation (S642) compared to low-risk tumors (58.3% vs 28.5%) , indicating the need for patient stratification.

• Immediate fixation or flash-freezing is critical, as Phospho-WEE1 (S642) signals can diminish with delayed preservation protocols.

• IHC optimization should include tissue-specific antigen retrieval protocols, with Tris-EDTA buffer (pH 9.0) for 20 minutes demonstrated to be effective for formalin-fixed paraffin-embedded tissues .

• Controls should include both normal adjacent tissue and tissue treated with alkaline phosphatase to confirm signal specificity.

What are the critical technical challenges in quantifying Phospho-WEE1 (S642) levels in response to therapeutic interventions?

Accurate quantification faces several technical challenges:

• Temporal dynamics: WEE1 S642 phosphorylation changes rapidly following drug treatments, with significant reductions observed as early as 8 hours post-treatment . This necessitates careful time-course experimental design.

• Total protein normalization: Since total WEE1 protein levels can decrease at M/G1 phase due to degradation , normalization strategies must account for treatment-induced changes in total protein.

• Multi-site phosphorylation interference: WEE1 undergoes phosphorylation at multiple sites (including S123 ), which may influence antibody accessibility to the S642 phosphorylation site.

• Signal amplification variances: Different detection methods (chemiluminescence, fluorescence) exhibit varying dynamic ranges for quantification, requiring appropriate standard curves.

• Drug-induced phosphatase activation: Some therapeutic agents may activate phosphatases that remove the S642 phosphorylation independent of effects on WEE1 activity or expression, complicating interpretation.

A robust approach involves parallel quantification of total WEE1, Phospho-WEE1 (S642), and downstream substrate phosphorylation (CDK1 Y15) to provide a comprehensive analysis of WEE1 pathway activity.

How can researchers resolve discrepancies between Phospho-WEE1 (S642) detection and downstream CDK1 phosphorylation status?

Resolving such discrepancies requires systematic investigation:

• Subcellular fractionation analysis: Since S642 phosphorylation affects nuclear-cytoplasmic localization, discrepancies may reflect compartmentalization rather than activity changes. Perform Western blot analysis on nuclear versus cytoplasmic fractions.

• Temporal sequence examination: CDK1 Y15 phosphorylation changes may lag behind or precede WEE1 S642 phosphorylation. Time-course experiments with frequent sampling can resolve temporal relationships.

• Additional regulatory pathway assessment: Examine parallel pathways affecting CDK1 phosphorylation status, particularly the CDC25 phosphatases which counteract WEE1 activity by removing inhibitory phosphorylations on CDK1 .

• Phosphatase activity measurement: Quantify specific phosphatases targeting CDK1 Y15, as increased phosphatase activity could mask elevated WEE1 kinase activity.

• Validation with kinase assays: Conduct in vitro kinase assays with immunoprecipitated WEE1 to directly measure its catalytic activity toward recombinant CDK1 substrates, providing functional correlation to phosphorylation status.

Research has shown that while AZD1775 (WEE1 inhibitor) and HDACIs (histone deacetylase inhibitors) individually have modest effects on reducing WEE1 S642 phosphorylation, their combination profoundly diminishes this phosphorylation and subsequently reduces CDK1 Y15 phosphorylation, indicating a potential synergistic mechanism worth exploring when discrepancies arise .

• Translational Research Applications

How does Phospho-WEE1 (S642) expression correlate with clinical outcomes in different cancer types?

Phospho-WEE1 (S642) expression demonstrates significant clinical correlations across cancer types:

Neuroblastoma:

• High-risk neuroblastoma patients show elevated Phospho-WEE1 (S642) expression (58.3% of samples) compared to low-risk patients (28.5%) .

• Immunohistochemical evidence from tissue microarrays representing 91 neuroblastoma patients confirmed increased levels of WEE1 phosphorylation in high-risk tumors .

• This suggests potential utility as a prognostic biomarker for risk stratification.

Breast Carcinoma:

• Immunohistochemical analysis of human breast carcinoma tissues reveals positive staining for Phospho-WEE1 (S642), which can be eliminated with alkaline phosphatase treatment, confirming specificity .

• The presence of activated WEE1 correlates with cell cycle checkpoint activation in tumor tissues.

Hematological Malignancies:

• In mastocytosis cell lines (HMC-1.1 and HMC-1.2), increased levels of p-WEE1(S642) were observed following treatment with Aurora kinase and Plk1 inhibitors .

• This hyperphosphorylation represented a clear sign of blocked cell transition into the mitotic phase and predicted response to combination therapy.

These correlations provide rationale for developing therapeutic strategies targeting the WEE1 pathway in specific cancer subtypes, particularly those with elevated Phospho-WEE1 (S642) as a biomarker of activation.

What is the optimal protocol for monitoring Phospho-WEE1 (S642) changes during combination therapy with checkpoint inhibitors?

Effective monitoring requires a comprehensive protocol addressing multiple parameters:

Sampling Timeline:

• Baseline measurement before treatment initiation

• Early assessment at 8 hours post-treatment (when initial phosphorylation changes become detectable)

• Intermediate assessment at 24 hours (when G2 arrest and WEE1 hyperactivation reach maximum)

• Late assessment at 48 hours (to observe sustained effects and potential recovery mechanisms)

Sample Processing:

• Immediate processing of samples is critical, as phosphorylation status can change rapidly

• Inclusion of phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) in lysis buffers

• Sample aliquoting for multiple analytical methods

Analytical Approach:

• Western blotting for simultaneous detection of:

  • Phospho-WEE1 (S642)

  • Total WEE1

  • Downstream markers: p-CDK1(Y15), p-cyclin B1(S133)

  • Upstream regulators: p-Chk1(S317), p-Chk2(T68)

  • DNA damage markers: γH2AX

Treatment Conditions:
When investigating WEE1 inhibitors (e.g., MK1775/AZD1775) in combination with other agents, two administration schedules should be compared:

• Sequential administration: First agent for 24h followed by WEE1 inhibitor

• Concomitant administration: Both agents administered simultaneously for 48h

Research has demonstrated that sequential treatment (e.g., Aurora kinase or Plk1 inhibitors followed by WEE1 inhibition) results in significantly higher rates of apoptosis compared to concomitant treatment , highlighting the importance of schedule optimization.

How can Phospho-WEE1 (S642) antibodies be used to predict sensitivity to WEE1 inhibitors in patient-derived samples?

Predicting sensitivity to WEE1 inhibitors using Phospho-WEE1 (S642) antibodies involves a multi-parameter assessment:

• Baseline phosphorylation quantification: Higher baseline Phospho-WEE1 (S642) levels may indicate increased dependency on WEE1 activity and potentially greater sensitivity to inhibitors. IHC staining intensity can be scored on a 0-3 scale and correlated with response metrics.

• Phosphorylation dynamics assessment: Ex vivo treatment of patient-derived cells with WEE1 inhibitors (e.g., AZD1775) for 24 hours followed by Western blot analysis of:

  • Reduction in Phospho-WEE1 (S642)

  • Corresponding decrease in CDK1 Y15 phosphorylation

  • Induction of DNA damage markers (γH2AX)

  More rapid/profound changes correlate with higher sensitivity.

• Cell cycle profile correlation: Flow cytometry analysis of cell cycle distribution before and after ex vivo WEE1 inhibitor treatment. Sensitive samples typically show:

  • Abrogation of G2/M arrest

  • Premature mitotic entry

  • Subsequent increase in sub-G1 population (apoptotic cells)

• Combined biomarker approach: Integration of Phospho-WEE1 (S642) data with p53 status, as p53-deficient cells often show enhanced sensitivity to WEE1 inhibition. A demonstrated relationship exists between p53 status and WEE1 dependency in neuroblastoma and other cancers .

• Therapeutic window assessment: Comparison of Phospho-WEE1 (S642) levels and inhibitor sensitivity between patient-derived tumor cells and matched normal cells to predict therapeutic window.

This approach provides a comprehensive framework for patient stratification and personalized treatment strategies involving WEE1 inhibitors.

• Integrative Research Questions

How does the interplay between WEE1 S642 phosphorylation and other post-translational modifications affect antibody detection and biological activity?

The complex interplay of post-translational modifications significantly impacts both detection and function:

• Hierarchical phosphorylation events:

  • WEE1 undergoes phosphorylation at multiple sites including S123 and S642 .

  • Phosphorylation at one site may structurally influence accessibility of other sites, affecting antibody binding efficiency.

  • Sequential phosphorylation patterns may occur, where modification of one site primes or inhibits modification of another.

• Antibody epitope accessibility:

  • Conformational changes induced by phosphorylation at adjacent sites can mask or expose the S642 epitope.

  • Studies comparing phospho-specific antibodies targeting different WEE1 residues show variable detection patterns during cell cycle progression, suggesting interdependence .

• Functional consequences of multi-site phosphorylation:

  • While S642 phosphorylation promotes nuclear-to-cytoplasmic translocation, other modifications may regulate:

    • Protein stability (hyperphosphorylation during M phase)

    • Catalytic activity toward CDK1

    • Protein-protein interactions beyond 14-3-3 binding

  • The temporal sequence of different phosphorylation events creates a regulatory code for WEE1 function.

• Detection optimization strategies:

  • Using multiple antibodies targeting different phosphorylation sites provides complementary information.

  • Pretreatment of samples with phosphatases followed by kinase reactions targeting specific residues can help resolve modification patterns.

  • Mass spectrometry-based approaches can quantify the stoichiometry of different phosphorylation combinations.

This complex modification landscape necessitates careful interpretation of antibody-based detection results and consideration of the broader post-translational context when studying WEE1 biology.

What are the most effective experimental designs to determine whether WEE1 S642 phosphorylation is a driver or consequence of cell cycle arrest?

Determining the causal relationship requires sophisticated experimental approaches:

• Site-directed mutagenesis studies:

  • Generate S642A (phospho-deficient) and S642D/E (phospho-mimetic) WEE1 mutants.

  • Express in WEE1-depleted backgrounds to examine effects on:

    • Cell cycle progression using flow cytometry

    • Nuclear/cytoplasmic localization using fractionation or imaging

    • CDK1 Y15 phosphorylation status

  • If S642D/E mutants induce G2 arrest independent of upstream signals, this supports a driver role.

• Temporal analysis with high resolution:

  • Synchronize cells and collect samples at short intervals (15-30 minutes).

  • Simultaneously measure:

    • WEE1 S642 phosphorylation

    • Cyclin B1-CDK1 activity

    • Nuclear envelope integrity

    • DNA condensation

  • Leading/lagging relationships suggest causality direction.

• Pharmacological decoupling experiments:

  • Use specific kinase inhibitors targeting Akt/PKB (upstream of S642 phosphorylation) .

  • Monitor effects on both S642 phosphorylation and cell cycle progression.

  • If S642 dephosphorylation precedes cell cycle effects, this supports a driver role.

• Single-cell correlation analysis:

  • Perform immunofluorescence for both Phospho-WEE1 (S642) and cell cycle markers.

  • Quantify at single-cell level to determine if heterogeneity in S642 phosphorylation predicts subsequent cell cycle decisions.

• Inducible expression systems:

  • Create cells with tetracycline-inducible WEE1 variants.

  • Monitor cell cycle effects upon rapid induction of wild-type versus S642 mutant proteins.

  • Rapid G2 arrest upon induction of phospho-mimetic but not phospho-deficient mutants would support a driver role.

These complementary approaches collectively provide strong evidence for determining the causal relationship between S642 phosphorylation and cell cycle regulation.

How can researchers integrate Phospho-WEE1 (S642) analysis with other cell cycle checkpoint markers for comprehensive pathway evaluation?

Comprehensive pathway evaluation requires systematic integration of multiple markers:

Experimental Framework for Integrated Analysis:

Integration Strategies:

• Multiplexed immunofluorescence: Simultaneous detection of Phospho-WEE1 (S642), p-CDK1(Y15), and DNA content in single cells to directly correlate modifications with cell cycle position.

• Sequential immunoblotting: Using the same membrane for detection of multiple phospho-proteins through sequential antibody stripping and reprobing.

• Correlation matrices: Statistical analysis of relationships between different markers across treatment conditions and time points.

• Pathway inhibitor combinations: Systematic application of inhibitors targeting different nodes (e.g., ATR, Chk1, WEE1, CDK1) to map pathway dependencies.

• Mathematical modeling: Integration of quantitative data into computational models that predict pathway behavior under various perturbations.

Research demonstrates the value of this integrated approach, as studies of combination therapy with AZD1775 and Vorinostat showed that combined treatment profoundly diminished WEE1 S642 phosphorylation along with CDK1 Y15 and T14 phosphorylation, providing mechanistic insight into synergistic effects .

• Emerging Research Directions

How might single-cell analysis techniques enhance our understanding of heterogeneous Phospho-WEE1 (S642) patterns in tumors?

Single-cell techniques offer transformative insights into WEE1 biology:

• Revealing intratumoral heterogeneity:

  • Traditional Western blot analysis of tumor lysates masks cellular heterogeneity.

  • Single-cell immunofluorescence can map Phospho-WEE1 (S642) distribution patterns within the tumor microenvironment.

  • This approach can identify resistant subpopulations with distinct WEE1 activation profiles.

• Correlating with cell cycle positions:

  • Combined staining for Phospho-WEE1 (S642), DNA content, and specific phase markers enables precise mapping of phosphorylation dynamics throughout the cell cycle at single-cell resolution.

  • This technique can identify aberrant WEE1 activation outside expected cell cycle phases in cancer cells.

• Multi-parameter analysis:

  • Combining Phospho-WEE1 (S642) detection with markers for:

    • Stemness/differentiation

    • Hypoxia

    • Proliferation

    • DNA damage

  • This creates multidimensional profiles of cellular states associated with specific WEE1 activation patterns.

• Spatial context integration:

  • Imaging mass cytometry or multiplexed ion beam imaging allows simultaneous detection of dozens of markers including Phospho-WEE1 (S642).

  • This preserves spatial relationships between cells with different WEE1 activation states and their microenvironmental context.

• Temporal dynamics tracking:

  • Live-cell imaging with fluorescent biosensors for WEE1 activity can track real-time changes in single cells.

  • This approach can reveal oscillatory patterns or transitions missed in population-averaged measurements.

These approaches collectively address the limitations of bulk analysis methods evident in current research, where heterogeneous responses to WEE1 inhibitors like AZD1775 have been observed but not fully characterized at the single-cell level.

What are the emerging approaches for studying the relationship between WEE1 S642 phosphorylation and DNA damage response pathways?

Cutting-edge approaches to investigate this relationship include:

• Proximity ligation assays (PLA):

  • Direct visualization of interactions between Phospho-WEE1 (S642) and DNA damage response proteins.

  • This technique can identify novel binding partners specifically interacting with the phosphorylated form of WEE1.

  • PLA can be performed in fixed cells or tissues, enabling translational applications.

• CRISPR-based genetic screens:

  • Genome-wide CRISPR screens in the presence of WEE1 inhibitors can identify synthetic lethal interactions.

  • Secondary screens with phospho-site mutants (S642A vs. S642D) can distinguish phosphorylation-dependent interactions.

  • This approach may identify novel therapeutic combinations targeting cells with aberrant WEE1 phosphorylation.

• ChIP-sequencing with Phospho-WEE1 (S642) antibodies:

  • Investigating potential chromatin association of phosphorylated WEE1.

  • This could reveal direct roles in DNA damage detection or repair beyond its canonical cytoplasmic function.

  • Integration with γH2AX ChIP-seq can map relationships to damage sites.

• Proteomic analysis of phosphorylation-dependent interactome:

  • Immunoprecipitation with Phospho-WEE1 (S642) antibodies followed by mass spectrometry.

  • Comparison of interacting proteins between normal and DNA damage conditions.

  • This approach can identify condition-specific interactions mediated by S642 phosphorylation.

• In situ analysis of replication stress sites:

  • Co-localization studies of Phospho-WEE1 (S642) with markers of replication stress.

  • This can reveal spatial relationships between WEE1 activity and sites of ongoing DNA replication problems.

  • Research already indicates connections between WEE1 inhibition and DNA damage, as combined AZD1775/Vorinostat treatment reduces both WEE1 S642 phosphorylation and increases DNA damage markers .

These approaches extend beyond traditional methods to explore mechanistic connections between WEE1 phosphorylation and the DNA damage response, potentially revealing new therapeutic opportunities.

How will the development of phospho-specific inhibitors targeting WEE1 S642 advance precision medicine strategies?

Phospho-specific inhibitors represent a frontier in targeted therapy development:

• Mechanism-based therapeutic precision:

  • Traditional WEE1 inhibitors like AZD1775/MK1775 target the catalytic domain, blocking all WEE1 functions .

  • Phospho-S642-specific inhibitors could:

    • Selectively disrupt 14-3-3 protein interactions

    • Alter subcellular localization without affecting catalytic activity

    • Target specific WEE1 functions while preserving others

  • This approach may reduce toxicity by targeting cancer-specific WEE1 dependencies.

• Biomarker-driven patient selection:

  • Phospho-WEE1 (S642) levels vary across tumor types, with high expression in certain cancers like high-risk neuroblastoma .

  • Antibody-based screening could identify patients likely to benefit from phospho-specific inhibitors.

  • The established correlation between Phospho-WEE1 (S642) and disease risk provides rationale for targeted intervention.

• Combination therapy optimization:

  • Phospho-specific inhibitors might synergize differently with other agents compared to catalytic inhibitors.

  • Sequential treatment approaches, shown to be effective with current WEE1 inhibitors , could be further refined.

  • Targeting specific phosphorylation events may overcome resistance mechanisms to catalytic inhibitors.

• Real-time therapy monitoring:

  • Phospho-WEE1 (S642) antibodies provide tools for monitoring:

    • Target engagement by phospho-specific inhibitors

    • Pathway adaptation during treatment

    • Emergence of resistance mechanisms

  • This enables dynamic adjustment of treatment strategies.

• Rational design of combination approaches:

  • Targeting upstream kinases responsible for S642 phosphorylation (Akt/PKB) in combination with downstream effectors.

  • Exploiting synthetic lethality based on phosphorylation status.

  • Developing bifunctional molecules that simultaneously target WEE1 phosphorylation and interacting proteins.

This evolving approach represents a paradigm shift from targeting protein expression or catalytic activity to targeting specific post-translational modifications, potentially increasing therapeutic precision.